Skip to main content
Equibles
NVCR logo

NVCR · NovoCure Ltd · Webcasts, Transcripts & Audio

Track NVCR — free

Use NVCR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NVCR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$13.15 +0.04 (+0.31%) At close · Oct 30 Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.54B
Shares
116.92M
Volume · Oct 30 1.97M Avg daily vol (3M) 1.44M

NovoCure Ltd Webcasts

Earnings calls, investor updates, investor days and conferences for NovoCure Ltd (NVCR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-29
NovoCure Ltd (NVCR) Q3 2026 Earnings Call Transcript
Confident tone Japan commercial expansion Core GBM growth and patient adoption Optune Pax U.S. launch challenges
Revenue
$193.40M
▲ 15.7% YoY
Diluted EPS
$-0.09
Gross margin
77.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-14
NovoCure Ltd (NVCR) September 14, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
NovoCure Ltd (NVCR) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-23
NovoCure Ltd (NVCR) Q2 2026 Earnings Call Transcript
Confident tone Clinical pipeline and label expansion Optune Lua Japan launch Germany launch and reimbursement
Revenue
$183.58M
▲ 15.6% YoY
Diluted EPS
$-0.13
Gross margin
77.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-30
NovoCure Ltd (NVCR) Q1 2026 Earnings Call Transcript
Confident tone Optune Pax pancreatic launch GBM / Optune Gio core business Panova-4 metastatic pancreatic data
Revenue
$174.06M
▲ 12.3% YoY
Diluted EPS
$-0.62
Gross margin
77.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
NovoCure Ltd (NVCR) Q4 2025 Earnings Call Transcript
Positive tone GBM core business and active patient growth Geographic expansion and new market launches Regulatory milestones and submissions
Revenue
$174.35M*
▲ 8.1% YoY
Gross margin
75.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-30
NovoCure Ltd (NVCR) Q3 2025 Earnings Call Transcript
Positive tone Lung cancer launch challenges GBM business growth Japan launch for lung cancer
Revenue
$167.20M
▲ 7.8% YoY
Diluted EPS
$-0.33
Gross margin
73.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-24
NovoCure Ltd (NVCR) Q2 2025 Earnings Call Transcript
Confident tone Optune Lua launch in non-small cell lung cancer PANOVA-3 pancreatic cancer data and PMA filing METIS brain metastases trial and FDA submission
Revenue
$158.81M
▲ 5.6% YoY
Diluted EPS
$-0.36
Gross margin
73.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-24
NovoCure Ltd (NVCR) Q1 2025 Earnings Call Transcript
Confident tone OptuneLua NSCLC US launch Panova-3 pancreatic cancer data at ASCO Reimbursement and revenue ramp
Revenue
$154.99M
▲ 11.9% YoY
Diluted EPS
$-0.31
Gross margin
75.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
NovoCure Ltd (NVCR) Q4 2024 Earnings Call Transcript
Confident tone GBM core business growth Optune Lua non-small cell lung cancer launch Gross margin and operating expense outlook
Revenue
$161.27M*
▲ 20.5% YoY
Gross margin
79.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-30
NovoCure Ltd (NVCR) Q3 2024 Earnings Call Transcript
Confident tone Optune Lua NSCLC launch Executive leadership transitions Reimbursement and CMS for lung
Revenue
$155.09M
▲ 21.8% YoY
Diluted EPS
$-0.28
Gross margin
77.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-25
NovoCure Ltd (NVCR) Q2 2024 Earnings Call Transcript
Confident tone Non-small cell lung cancer (NSCLC) launch readiness Glioblastoma (GBM) commercial growth Clinical pipeline progress
Revenue
$150.36M
▲ 19.3% YoY
Diluted EPS
$-0.31
Gross margin
77.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
NovoCure Ltd (NVCR) Q1 2024 Earnings Call Transcript
Positive tone METIS Phase III trial in brain metastases INNOVATE-3 ovarian cancer data LUNAR / NSCLC regulatory pathway
Revenue
$138.50M
▲ 13.4% YoY
Diluted EPS
$-0.36
Gross margin
75.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
NovoCure Ltd (NVCR) Q4 2023 Earnings Call Transcript
Confident tone Lung cancer launch (LUNAR) Clinical pipeline readouts GBM commercial growth
Revenue
$133.78M*
▲ 4.2% YoY
Gross margin
75.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-10-26
NovoCure Ltd (NVCR) Q3 2023 Earnings Call Transcript
Revenue
$127.32M
▼ 2.8% YoY
Diluted EPS
$-0.46
Gross margin
74.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-07-27
NovoCure Ltd (NVCR) Q2 2023 Earnings Call Transcript
Revenue
$126.05M
▼ 10.5% YoY
Diluted EPS
$-0.54
Gross margin
73.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
NovoCure Ltd (NVCR) Q1 2023 Earnings Call Transcript
Revenue
$122.18M
▼ 11.2% YoY
Diluted EPS
$-0.50
Gross margin
75.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
NovoCure Ltd (NVCR) Q4 2022 Earnings Call Transcript
Revenue
$128.43M
▼ 3.6% YoY
Diluted EPS
$-0.36
Gross margin
77.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-10-27
NovoCure Ltd (NVCR) Q3 2022 Earnings Call Transcript
Revenue
$131.00M
▼ 2% YoY
Diluted EPS
$-0.25
Gross margin
77.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
NovoCure Ltd (NVCR) Q2 2022 Earnings Call Transcript
Revenue
$140.87M
▲ 5.5% YoY
Diluted EPS
$-0.23
Gross margin
79.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
NovoCure Ltd (NVCR) Q1 2022 Earnings Call Transcript
Revenue
$137.55M
▲ 2.1% YoY
Diluted EPS
$-0.04
Gross margin
79.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
NovoCure Ltd (NVCR) Q4 2021 Earnings Call Transcript
Revenue
$133.21M
▼ 7.5% YoY
Diluted EPS
$-0.25
▼ 725% YoY
Gross margin
77.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-28
NovoCure Ltd (NVCR) Q3 2021 Earnings Call Transcript
Revenue
$133.61M
▲ 0.7% YoY
Diluted EPS
$-0.13
▼ 244.4% YoY
Gross margin
77.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
NovoCure Ltd (NVCR) Q2 2021 Earnings Call Transcript
Revenue
$133.52M
▲ 15.2% YoY
Diluted EPS
$-0.14
▼ 800% YoY
Gross margin
78.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
NovoCure Ltd (NVCR) Q1 2021 Earnings Call Transcript
Revenue
$134.69M
▲ 32.3% YoY
Diluted EPS
$-0.04
▼ 200% YoY
Gross margin
80.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
NovoCure Ltd (NVCR) Q4 2020 Earnings Call Transcript
Revenue
$143.95M
▲ 45.1% YoY
Diluted EPS
$0.04
▲ 0% YoY
Gross margin
80.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-29
NovoCure Ltd (NVCR) Q3 2020 Earnings Call Transcript
Revenue
$132.66M
▲ 44.1% YoY
Diluted EPS
$0.09
▲ 350% YoY
Gross margin
78.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
NovoCure Ltd (NVCR) Q2 2020 Earnings Call Transcript
Revenue
$115.92M
▲ 33.7% YoY
Diluted EPS
$0.02
Gross margin
78.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
NovoCure Ltd (NVCR) Q1 2020 Earnings Call Transcript
Revenue
$101.83M
▲ 38.9% YoY
Diluted EPS
$0.04
Gross margin
75.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
NovoCure Ltd (NVCR) Q4 2019 Earnings Call
Revenue
$99.23M
▲ 42.4% YoY
Diluted EPS
$0.04
Gross margin
75.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–30 of 30 webcasts
Key facts CIK 1645113 CUSIP G6674U108 13F (30d) 60 filings 52 filers Visit website Investor relations